The FDA-listed REPATHA label for evolocumab was revised effective August 19, 2026. The change affects the product’s Indications and Usage section, which states that REPATHA is indicated to reduce the risk of major adverse cardiovascular events in adults.
The supplied label summary identifies the covered events as cardiovascular death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization. The record does not provide additional details about the affected adult population beyond the wording shown in the indication summary.
Background
REPATHA is the brand name listed for evolocumab. In the supplied FDA label update, the drug’s indication is framed around reducing the risk of major adverse cardiovascular, or CV, events. The listed event components are CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, and coronary revascularization.
The available data identify this as an indication and usage revision rather than a clinical-trial results posting. They do not provide a dosing change, a new mechanism description, prevalence information, or details of prior approvals.
What this means
For clinicians, researchers, patient advocates, and editors tracking REPATHA, the key change is that the FDA-linked label in the source record contains revised Indications and Usage language effective August 19, 2026. The indication describes risk reduction for a defined group of major adverse cardiovascular events in adults.
The supplied record does not state which specific words were added or removed compared with the previous label, and it does not include eligibility criteria, treatment duration, comparative efficacy figures, safety findings, or supporting statistical analyses. Those details should not be inferred from the indication summary alone.
Source
Source: FDA, REPATHA prescribing-label document, effective August 19, 2026. The document is available through DailyMed at dailymed.nlm.nih.gov.